Metabolic complications with the use of mTOR inhibitors for cancer therapy.

[1]  J. Machiels,et al.  Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Ettinger,et al.  A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas , 2011, Cancer.

[3]  J. Blay,et al.  Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[5]  R. Broaddus,et al.  A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma , 2010, Cancer.

[6]  S. Dacic,et al.  Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[7]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[8]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[9]  R. Wolff,et al.  Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies , 2010, BMC Cancer.

[10]  M. Robson,et al.  Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Baudin,et al.  Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Eric Sauerbrei,et al.  Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[14]  J. Douketis,et al.  The devil is in the detailsor not? A primer on individual patient data meta-analysis , 2009, Annals of Internal Medicine.

[15]  R. Greil,et al.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Amato,et al.  A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer , 2009, Cancer.

[17]  Jeffrey W. Clark,et al.  Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Hidalgo,et al.  A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[20]  Allison Gruner Gandhi,et al.  The Devil Is in the Details , 2007, Evaluation review.

[21]  G. Pond,et al.  A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas , 2006, British Journal of Cancer.

[22]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[23]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[26]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[28]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[29]  J. Blay,et al.  Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[31]  R. Pearson.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2011 .

[32]  J. Douketis,et al.  ACP Journal Club. The devil is in the details...or not? A primer on individual patient data meta-analysis. , 2009, Annals of Internal Medicine.

[33]  J. Doroshow,et al.  CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. , 2004, Cancer.